A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Ralinepag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms ADVANCE EXTENSION
- Sponsors Arena Pharmaceuticals; United Therapeutics Corporation
- 01 May 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Apr 2019 to 1 Jun 2019.
- 04 Apr 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 September 2018 to 1 Apr 2019.
- 01 Oct 2018 New trial record